Cerebral Amyloid Angiopathy - Market Insights, Epidemiology, and Market Forecast - 2034

Key Highlights:

• The rise in cases of CAA is primarily attributed to aging populations, increased use of advanced neuroimaging techniques, and growing awareness among clinicians. As longevity improves, age-related neurological conditions like CAA become more prevalent, leading to higher detection rates and more frequent diagnosis in older individuals.
• Despite growing prevalence, CAA remains without an approved treatment. Current management focuses solely on symptom control and prevention of complications. This highlights a pressing unmet need for targeted therapies that can halt or reverse disease progression, offering patients more definitive and effective options beyond supportive care alone.
• The therapeutic pipeline for CAA remains sparse, with few investigational candidates such as Mivelsiran (ALN-APP) from Alnylam Pharmaceuticals. This limited landscape underscores an urgent need for greater industry engagement. More companies should invest in innovative research to develop targeted treatments and address the significant unmet needs of patients affected by CAA.
• In July 2024, the Alnylam Pharmaceuticals initiated a cAPPricorn-1 Phase II study of Mivelsiran (ALN-APP) for the treatment of CAA.

DelveInsight's comprehensive report titled "Cerebral Amyloid Angiopathy (CAA) - Market Insights, Epidemiology, and Market Forecast - 2034" offers a detailed analysis of CAA. The report presents historical and projected epidemiological data covering Diagnosed Prevalent Cases of CAA, Severity-specific Diagnosed Prevalent Cases of CAA, Gender-specific Diagnosed Prevalent Cases of CAA, and Age-specific Diagnosed Prevalent Cases of CAA. In addition to epidemiology, the market report encompasses various aspects related to the patient population. These aspects include the diagnosis process, prescription patterns, physician perspectives, market accessibility, treatment options, and prospective developments in the market across seven major markets: the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan, spanning from 2020 to 2034.

The report analyzes the existing treatment practices and unmet medical requirements in CAA. It evaluates the market potential and identifies potential business prospects for enhancing therapies or interventions. This valuable information enables stakeholders to make well-informed decisions regarding product development and strategic planning for the market.

Cerebral Amyloid Angiopathy (CAA) Overview

CAA is a cerebrovascular condition marked by the buildup of amyloid beta-peptides in the leptomeninges and small to medium cerebral vessels, leading to vessel fragility and potential lobar intracerebral hemorrhage (ICH). It can also manifest as cognitive decline, microbleeds, hemosiderosis, inflammatory white matter changes, Alzheimer's disease, or transient neurological symptoms. CAA may be sporadic or linked to familial syndromes. Diagnosis relies on clinical, imaging, and pathological evidence, with definitive confirmation possible only through postmortem brain examination. No approved disease-modifying therapies exist, and prognosis worsens with larger hemorrhages and advancing age.

Cerebral Amyloid Angiopathy (CAA) Diagnosis and Treatment Overview

CAA diagnosis relies on clinical, radiographic, and pathological criteria. The Boston criteria 2.0 are widely used to assess CAA probability, requiring either brain MRI or biopsy data for definitive diagnosis, though possible and probable diagnoses can be made through clinicoradiological findings. In cases involving lobar intracerebral hemorrhage without MRI, the Edinburgh criteria can guide assessment. For suspected iatrogenic CAA, the modified Queen Square criteria are proposed. Definitive diagnosis remains limited to postmortem examination.

Currently, there are no approved disease-modifying therapies for CAA. Investigational approaches target beta-amyloid clearance through antibody-mediated removal, reduction in production, and enhancement of physiological clearance. These may cause amyloid-related imaging abnormalities (ARIA). Use of anticoagulants and thrombolytics is cautioned due to increased hemorrhage risk, while antiplatelets may be used if clinically indicated. Risk of recurrent hemorrhage is highest within the first three months post-ICH, often occurring near the initial bleed site.

Cerebral Amyloid Angiopathy (CAA) Epidemiology

The epidemiology section of the CAA market report offers information on the patient populations, including historical and projected trends for each of the seven major markets. Examining key opinion leader views from physicians or clinical experts can assist in identifying the reasons behind historical and projected trends. The diagnosed patient pool, their trends, and the underlying assumptions are all included in this section of the report.

This section also presents the data with relevant tables and graphs, offering a clear and concise view of the prevalence of CAA. Additionally, the report discloses the assumptions made during the analysis, ensuring data interpretation and presentation transparency. This epidemiological data is valuable for understanding the disease burden and its impact on the patient population across various regions.

Key Findings

• A study involving Western populations across Europe and the US found that 46% of individuals exhibited mild-to-severe CAA, while 23.5% showed moderate-to-severe manifestations. These findings underscore a significant burden of the disease within these regions.
• Based on secondary analysis, CAA appears to be more prevalent in women than in men within the US population aged 40 to 90. Specifically, the condition affects approximately 28% of women, compared to 18.3% of men, indicating a notable sex-based difference in CAA occurrence across this age range.
• Secondary analysis shows that in Italy, CAA affects around 5-9% of people aged 60-69, and its occurrence rises significantly to about 43-58% in those over 90.
• Secondary analysis indicates that CAA affects approximately 28.5% of the population in Japan, reflecting a considerable disease prevalence within this East Asian demographic.

Cerebral Amyloid Angiopathy (CAA) Market Outlook

The CAA therapeutics market is further expected to increase by the major drivers, such as the rising prevalent population, technological advancements, and upcoming therapies in the forecast period (2025-2034).

CAA currently has no approved disease-modifying therapies, highlighting a major therapeutic gap. Management is largely symptomatic and relies on off-label use of various medications. Clinicians often adopt supportive strategies such as strict blood pressure control, and cautious use of antithrombotics to mitigate hemorrhagic risk. These approaches are tailored to individual patient profiles, though none target the underlying amyloid pathology. The absence of standardized treatments underscores the urgent need for targeted research and novel therapeutic development in CAA.

With ongoing research and continued dedication, the future holds hope for even more effective treatments and, ultimately, a cure for this challenging condition. According to DelveInsight, the CAA market in the 7MM is expected to change significantly during the forecast period (2025-2034).

Cerebral Amyloid Angiopathy (CAA) Drug Chapters

Emerging Drugs

Mivelsiran (ALN-APP): Alnylam Pharmaceuticals

Mivelsiran is an experimental RNA interference (RNAi) therapy administered by intrathecal route and being developed for CAA. Its mechanism involves selectively silencing APP mRNA within the central nervous system, which may lead to reduced production of amyloid precursor protein and its related cleavage products most notably amyloid beta (AB), a key contributor to CAA pathology. By targeting the source of amyloid generation, Mivelsiran aims to address the underlying disease process rather than just the symptoms.

• The drug is currently in the Phase II of clinical trial for the management of CAA.

Cerebral Amyloid Angiopathy (CAA) Market Segmentation

DelveInsight's 'Cerebral Amyloid Angiopathy (CAA) - Market Insights, Epidemiology, and Market Forecast - 2034' report provides a detailed outlook of the current and future CAA market, segmented within countries, by therapies, and by classes. Further, the market of each region is then segmented by each therapy to provide a detailed view of the current and future market share of all therapies.

Cerebral Amyloid Angiopathy (CAA) Market Size by Countries

The CAA market size is assessed separately for various countries, including the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan. In 2024, the United States held a significant share of the overall 7MM (Seven Major Markets) CAA market, primarily attributed to the country's higher prevalence of the condition and the elevated cost of the available treatments. This dominance is projected to persist, especially with the potential early introduction of new products.

Cerebral Amyloid Angiopathy (CAA) Market Size by Therapies

CAA Market Size by Therapies is categorized into current and emerging markets for the study period 2020-2034.

Cerebral Amyloid Angiopathy (CAA) Drugs Uptake

This section focuses on the sales uptake of potential CAA drugs that have recently been launched or are anticipated to be launched in the CAA market between 2025 and 2034. It estimates the market penetration of CAA drugs for a given country, examining their impact within and across classes and segments. It also touches upon the financial and regulatory decisions contributing to the probability of success (PoS) of the drugs in the CAA market.

The emerging CAA therapies are analyzed based on various attributes such as efficacy and safety in randomized clinical trials, order of entry and other market dynamics, and the unmet need they fulfill in the CAA market.

Cerebral Amyloid Angiopathy (CAA) Market Access and Reimbursement

DelveInsight's "Cerebral Amyloid Angiopathy (CAA) - Market Insights, Epidemiology, and Market Forecast - 2034" report provides a descriptive overview of the market access and reimbursement scenario of CAA. This section includes a detailed analysis of the country-wise healthcare system for each therapy, enlightening the market access, reimbursement policies, and health technology assessments.

KOL Views

To keep up with current CAA market trends and to fill gaps in secondary findings, we interview KOLs' and SMEs' working in the CAA domain. Their opinion helps understand and validate current and emerging therapies and treatment patterns or CAA market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the CAA unmet needs.

Cerebral Amyloid Angiopathy (CAA): KOL Insights

DelveInsight's analysts connected with 20+ KOLs to gather insights; however, interviews were conducted with 10+ KOLs in the 7MM. These KOLs were from organizations, institutes, and hospitals, such as, Massachusetts General Hospital, US, Department of Medicine and Surgery, University of Perugia, Italy; Goethe University, Germany; Institute of Prion Diseases, United Kingdom; Kumamoto University, Kumamoto, Japan, Hirosaki University Graduate School of Medicine, Japan among others.

"CAA remains a major unmet medical need due to the absence of approved disease-modifying therapies. Current management is limited to symptom control, lacking interventions that address the underlying pathology. There's a pressing demand for targeted treatments, early diagnostic tools, and better risk stratification approaches."

"Clinicians should remain vigilant for symptoms such as new-onset headaches, seizures, focal neurological deficits, and acute or subacute cognitive changes, which may signal inflammatory CAA and warrant immediate evaluation and treatment."

"Treatment focuses on managing symptoms, controlling blood pressure, preventing intracerebral hemorrhage, and avoiding anticoagulants. Supportive care, patient monitoring, and secondary stroke prevention are emphasized. Emerging therapies are under investigation, but none are yet established or approved for CAA treatment."

Competitive Intelligence Analysis

We conduct a Competitive and Market Intelligence analysis of the CAA. Market, utilizing various Competitive Intelligence tools such as SWOT analysis and Market entry strategies. The inclusion of these analyses is contingent upon data availability, ensuring a comprehensive and well-informed assessment of the market landscape and competitive dynamics.

Cerebral Amyloid Angiopathy (CAA) Pipeline Development Activities

The report offers an analysis of therapeutic candidates in Phase II and III stages and examines companies involved in developing targeted therapeutics for CAA. It provides valuable insights into the advancements and progress of potential treatments in clinical development for this condition.

Pipeline Development Activities

The report covers information on collaborations, acquisition and merger, licensing, patent details, and other information for emerging CAA therapies.

Cerebral Amyloid Angiopathy (CAA) Report Insights

• CAA Patient Population
• Therapeutic Approaches
• CAA Pipeline Analysis
• CAA Market Size and Trends
• CAA Market Opportunities
• Impact of Upcoming Therapies

Cerebral Amyloid Angiopathy (CAA) Report Key Strengths

• 10 Years Forecast
• The 7MM Coverage
• CAA Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed CAA Market
• CAA Drugs Uptake

Cerebral Amyloid Angiopathy (CAA) Report Assessment

• CAA Current Treatment Practices
• Unmet Needs
• CAA Product Profiles
• CAA Market Attractiveness

Key Questions:

• How common is CAA?
• What are the key findings of CAA epidemiology across the 7MM, and which country will have the highest number of patients during the study period (2020-2034)?
• What are the currently available treatments for CAA?
• What are the disease risk, burden, and unmet needs of CAA?
• At what CAGR is the CAA market and its epidemiology is expected to grow in the 7MM during the forecast period (2025-2034)?
• How would the unmet needs impact the CAA market dynamics and subsequently influence the analysis of the related trends?
• What would be the forecasted patient pool of CAA in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan?
• Among EU4 and the UK, which country will have the highest number of patients during the forecast period (2025-2034)?
• How many companies are currently developing therapies for the treatment of CAA?

Reasons to buy:

• The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the CAA market.
• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand the existing market opportunity in varying geographies and the growth potential over the coming years.
• Distribution of historical and current patient share based on real-world prescription data along with reported sales of current treatment in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan.
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the attribute analysis section to provide visibility around leading classes.
• Highlights of Market Access and Reimbursement policies of approved therapies, barriers to accessibility of off-label expensive therapies, and patient assistance programs.
• To understand the perspective of Key Opinion Leaders around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.

Frequently Asked Questions:

1. What are the treatment goals for CAA?

Treatment goals for CAA focus on minimizing cerebral hemorrhage risk, managing associated cognitive decline, and preserving neurological function. Supportive care involves blood pressure control and avoidance of anticoagulants where possible. Monitoring disease progression and addressing coexisting conditions like Alzheimer's are crucial. While no disease-modifying therapy exists, emerging research targets amyloid clearance and vascular protection to slow progression and improve quality of life.

2. What are the challenges in managing CAA?

Managing CAA is complex due to the lack of disease-modifying treatments and difficulties in early diagnosis. Risks of intracerebral hemorrhage limit therapeutic options, especially anticoagulation. Overlapping symptoms with other neurodegenerative disorders hinder clinical distinction. Monitoring disease progression remains difficult, and individualized care is essential. Moreover, balancing stroke prevention with bleeding risk presents ongoing clinical dilemmas, making effective long-term management a major challenge.

3. What are the key factors driving the growth of the CAA market?

CAA market is expanding due to rising awareness, increasing elderly population, and the growing recognition of its link to Alzheimer's disease. Advances in neuroimaging and biomarkers are enabling earlier diagnosis and targeted research. Unmet clinical needs and the absence of disease-modifying therapies are prompting pharmaceutical innovation. Supportive policy changes and growing investment in neurological disorders further catalyze market growth and therapeutic exploration.

4. How will the CAA Market and Epidemiology Forecast Report benefit the clients?

The CAA Market and Epidemiology Forecast Report offers clients strategic insights into disease prevalence, patient segmentation, and market dynamics. It helps identify commercial opportunities, assess treatment gaps, and support planning for product development, market entry, or expansion. The report also aids stakeholders in understanding regulatory landscapes, forecasting trends, and making data-driven investment or policy decisions.